David J. Sweeny

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

David J. Sweeny, Weiqun Li, Jeffrey Clough et al. · Drug Metabolism and Disposition · 2010 · 89 citations

Medicine, Pharmacokinetics, Pharmacology +17

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

John McLaughlin, Vadim Markovtsov, Hui Li et al. · Journal of Cancer Research and Clinical Oncology · 2009 · 68 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +10

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Joshua Haznedar, Shem Patyna, Carlo L. Bello et al. · Cancer Chemotherapy and Pharmacology · 2009 · 64 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

AMPK Activation through Mitochondrial Regulation Results in Increased Substrate Oxidation and Improved Metabolic Parameters in Models of Diabetes

Yonchu Jenkins, Tian‐Qiang Sun, Vadim Markovtsov et al. · PLoS ONE · 2013 · 56 citations · Full text

Life Sciences, Biochemistry, Physiology +17

Metabolism of the Influenza Neuraminidase Inhibitor Prodrug Oseltamivir in the Rat

David J. Sweeny, Geoffrey Lynch, Alison M. Bidgood et al. · Drug Metabolism and Disposition · 2000 · 40 citations

Medicine, Pharmacokinetics, Pharmacology +14